



Cardiology Network

AEPC – Task Force for Drugs and Therapeutics in Paediatric Cardiology

EnPR EMA Workshop
London, June 27th 2013

Sylvie DI FILIPPO



AEPC

www.aepc.org

- **Association for European Paediatric Cardiology**
- Founded in 1963
- < 1000 members from Europe
- AEPC Council
 - Need for organization and coordination of Research and Trials in Paediatric Cardiology
 - Most of drugs are off-label used
 - Very few PIPs

Task Force for Drugs and Therapeutics in Paediatric Cardiology



- Nucleus
- Network of members : expert centres of excellence in Europe
- Collaboration with Enpr EMA
- First meeting in London April 9th
- First business meeting in London, AEPC annual meeting May 25th



Objectives of the TF

- Promote Research on therapeutics (medicines, devices) to increase the availability of authorised products.
- To create a European network of research centres and networks of excellence
- Define therapeutic needs and priorities
- Provide a platform for initiation of trials
- Focus on quality, safety and efficacy for their use in children
- To facilitate multicentre trials and European centres collaboration
- To improve the development and utilization of therapeutics in children with cardiac disease.



Start of Cardiology Network

- **54 centers from 17 countries applied**
 - 13 UK
 - 8 France
 - 4 Germany
 - 3 Austria
 - 2 Italy, 2 Spain, 2 Portugal
 - 2 Netherlands, 2 Finland, 1 Sweden, 1 Iceland, 1 Ireland
 - 4 Romania, 5 Russia, 3 Czech Republik and 1 Poland.
- All conduct multicentric studies, industry-sponsored and accademic



First issues

- Network including centres of excellence
- Define drugs and areas of main interest
 - Heart failure
 - Pulmonary hypertension
 - Devices
 - Antiarrhythmic drugs
- Coordonnate and enhance relationships
- Studies on drugs pharmacokinetics
- Guidelines and recommendations
- Scimitar study Registry (Italy)